Statin therapy and plasma coenzyme Q10 concentrations - A systematic review and meta-analysis of placebo-controlled trials

Pharmacological Research

Volumn 99, Issue , 2015, Pages 329-336

  Banach, Maciej ^a   Serban, Corina ^b   Ursoniu, Sorin ^b   Rysz, Jacek ^a   Muntner, Paul ^c   Toth, Peter P ^d,e   Jones, Steven R ^e   Rizzo, Manfredi ^f   Glasser, Stephen P ^g   Watts, Gerald F ^h   Blumenthal, Roger S ^e   Lip, Gregory Y H ⁱ   Mikhailidis, Dimitri P ^j   Sahebkar, Amirhossein ^k  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d CGH Medical Center   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f UNIVERSITY OF PALERMO   (Italy)

^g University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^j ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^k MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

Coenzyme Q10; Mitochondrial dysfunction; Myopathy; Statin therapy; Ubiquinone

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE; UBIQUINONE;

ARTICLE; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; ENZYME BLOOD LEVEL; HUMAN; HYDROPHILICITY; HYPERCHOLESTEROLEMIA; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; DOUBLE BLIND PROCEDURE; FEMALE; MALE; MIDDLE AGED; PLACEBO EFFECT;

ADULT; AGED; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UBIQUINONE;

EID: 84938084844     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.07.008     Document Type: Article

References (50)

1. M.A. Desbats, G. Lunardi, M. Doimo, E. Trevisson, and L. Salviati Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency J. Inherit. Metab. Dis. 38 2015 145 156
2. S. Pepe, S.F. Marasco, S.J. Haas, F.L. Sheeran, H. Krum, and F.L. Rosenfeldt Coenzyme Q 10 in cardiovascular disease Mitochondrion 7 2007 S154 S167
3. E. Fontaine, F. Ichas, and P. Bernardi A ubiquinone-binding site regulates the mitochondrial permeability transition pore J. Biol. Chem. 273 1998 25734 25740
4. A. Ayer, P. Macdonald, and R. Stocker CoQ 10 in heart failure and ischemic heart disease Annu. Rev. Nutr. 2015 35
5. A. Bargossi, M. Battino, A. Gaddi, and et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors Int. J. Clin. Lab. Res. 24 1994 171 176
6. K. Kędziora-Kornatowska, J. Czuczejko, J. Motyl, and et al. Effects of coenzyme Q10 supplementation on activities of selected antioxidative enzymes and lipid peroxidation in hypertensive patients treated with indapamide. A pilot study Arch. Med. Sci. 6 2010 513 518
7. D.A. Groneberg, B. Kindermann, M. Althammer, Q. Coenzyme, and et al. 10 affects expression of genes involved in cell signalling, metabolism and transport in human CaCo-2 cells Int. J. Biochem. Cell Biol. 37 2005 1208 1218
8. A. Mellors, and A.L. Tappel The inhibition of mitochondrial peroxidation by ubiquinone and ubiquinol J. Biol. Chem. 241 1966 4353 4356
9. M. Banach, M. Rizzo, P.P. Toth, and et al. Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel Arch. Med. Sci. 11 2015 1 23
10. R. Deichmann, C. Lavie, and S. Andrews Coenzyme Q10 and statin-induced mitochondrial dysfunction Ochsner J. 10 2010 16 21
11. M. Banach, M. Rizzo, P.P. Toth, and et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel Expert Opin. Drug Saf. 14 6 2015 935 955
12. P. Sirvent, J. Mercier, and A. Lacampagne New insights into mechanisms of statin-associated myotoxicity Curr. Opin. Pharmacol. 8 2008 333 338
13. G.M. Camerino, M.A. Pellegrino, L. Brocca, and et al. Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle Biochem. Pharmacol. 81 2011 1054 1064
14. E.S. Stroes, P.D. Thompson, A. Corsini, and et al. Statin-associated muscle symptoms: impact on statin therapy - European Atherosclerosis society consensus panel statement on assessment, aetiology and management Eur. Heart J. 36 17 2015 1012 1022
15. M. Banach, C. Serban, A. Sahebkar, and et al. Effects of coenzyme Q10 on statin-induced myopathy Mayo Clin. Proc. 90 2015 24 34
16. L. Marcoff, and P.D. Thompson The role of coenzyme Q10 in statin-associated myopathy: a systematic review J. Am. Coll. Cardiol. 49 2007 2231 2237
17. I. Buhaescu, and H. Izzedine Mevalonate pathway: a review of clinical and therapeutical implications Clin. Biochem. 40 2007 575 584
18. G. Dallner, and P.J. Sindelar Regulation of ubiquinone metabolism Free Radic. Biol. Med. 29 2000 285 294
19. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman, and P. Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
20. M. Borenstein, L. Hedges, J. Higgins, and H. Rothstein Comprehensive Meta-analysis Version 2 2005 Biostat Englewood, NJ 104
21. S.P. Hozo, B. Djulbegovic, and I. Hozo Estimating the mean and variance from the median, range, and the size of a sample BMC Med. Res. Methodol. 5 2005 13
22. A. Sahebkar Does PPARγ2 gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a meta-analysis DNA Cell Biol. 32 2013 188 198
23. A. Sahebkar Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a Meta-analysis Phytother. Res. 28 2014 633 642
24. S. Duval, and R. Tweedie Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis Biometrics 56 2000 455 463
25. E. Ashton, E. Windebank, M. Skiba, and et al. Why did high-dose rosuvastatin not improve cardiac remodeling in chronic heart failure? Mechanistic insights from the UNIVERSE study Int. J. Cardiol. 146 2011 404 407
26. A. Jula, J. Marniemi, R. Huupponen, A. Virtanen, M. Rastas, and T. Rönnemaa Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial Jama 287 2002 598 605
27. W.A. Oranje, J.-P.J. Sels, G.J. Rondas-Colbers, P.J. Lemmens, and B.H. Wolffenbuttel Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients Clin. Chim. Acta 311 2001 91 94
28. H. Päivä, K.M. Thelen, R. Van Coster, and et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial Clin. Pharmacol. Ther. 78 2005 60 68
29. C.H. Strey, J.M. Young, S.L. Molyneux, and et al. Endothelium-ameliorating effects of statin therapy and coenzyme Q10 reductions in chronic heart failure Atherosclerosis 179 2005 201 206
30. G. Ghirlanda, A. Oradei, A. Manto, and et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study J. Clin. Pharmacol. 33 1993 226 229
31. Green S., Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.
32. M. Banach, W.S. Aronow, C. Serban, and et al. Lipids, blood pressure and kidney update 2014 Pharmacol. Res. 95-96C 2015 111 125
33. M. Banach, and D.P. Mikhailidis Lipid, blood pressure meta-analysis collaboration G. In reply-coenzyme Q10 and statin-induced myopathy Mayo Clin. Proc. 90 2015 420 421
34. G.P. Littarru, P. Langsjoen, and Q. Coenzyme 10 and statins: biochemical and clinical implications Mitochondrion 7 2007 S168 S174
35. D. Yubero, R. Montero, R. Artuch, J.M. Land, S.J. Heales, and I.P. Hargreaves Biochemical diagnosis of coenzyme q10 deficiency Mol. Syndromol. 5 2014 147 155
36. S. Larsen, N. Stride, M. Hey-Mogensen, and et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance J. Am. Coll. Cardiol. 61 2013 44 53
37. M. Fukami, N. Maeda, J. Fukushige, and et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits Res. Exp. Med. 193 1993 263 273
38. 10: could it have a role in cancer management? BioFactors 9 1999 365 370
39. M.W. Donnino, M.N. Cocchi, J.D. Salciccioli, and et al. Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock Crit. Care 15 2011 R189
40. K.A. Sewright, P.M. Clarkson, and P.D. Thompson Statin myopathy: incidence, risk factors, and pathophysiology Curr. Atheroscler. Rep. 9 2007 389 396
41. S.L. Di Stasi, T.D. MacLeod, J.D. Winters, and S.A. Binder-Macleod Effects of statins on skeletal muscle: a perspective for physical therapists Phys. Ther. 90 2010 1530 1542
42. 10. A review of animal and human publications BioFactors 18 2003 101 111
43. E. Alcocer-Gómez, J.A. Sánchez-Alcázar, and M.D. Cordero Coenzyme Q10 regulates serotonin levels and depressive symptoms in fibromyalgia patients: results of a small clinical trial J. Clin. Psychopharmacol. 34 2014 277 278
44. M. Bauer, A. Heinz, and P. Whybrow Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain Mol. Psychiatry 7 2001 140 156
45. L. Bazzichi, G. Giannaccini, L. Betti, and et al. ATP, calcium and magnesium levels in platelets of patients with primary fibromyalgia Clin. Biochem. 41 2008 1084 1090
46. M. Barylski, D. Nikolic, M. Banach, P. Toth, G. Montalto, and M. Rizzo Statins and new-onset diabetes Curr. Pharm. Des. 20 2014 3657 3664
47. M. Banach, M. Malodobra-Mazur, A. Gluba, N. Katsiki, J. Rysz, and A. Dobrzyn Statin therapy and new-onset diabetes: molecular mechanisms and clinical relevance Curr. Pharm. Des. 19 2013 4904 4912
48. N. Katsiki, and M. Banach Statins and the risk of diabetes: the debate Arch. Intern. Med. 172 2012 895 896
49. Y.S. Chatzizisis, C. Vaklavas, and G.D. Giannoglou Coenzyme Q10 depletion: etiopathogenic or predisposing factor in statin associated myopathy Am. J. Cardiol. 101 2008 1071
50. C. Vaklavas, Y.S. Chatzizisis, A. Ziakas, C. Zamboulis, and G.D. Giannoglou Molecular basis of statin-associated myopathy Atherosclerosis 202 2009 18 28